Yoshimi Imura

1.2k total citations
31 papers, 1.0k citations indexed

About

Yoshimi Imura is a scholar working on Cardiology and Cardiovascular Medicine, Molecular Biology and Pharmacology. According to data from OpenAlex, Yoshimi Imura has authored 31 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Cardiology and Cardiovascular Medicine, 10 papers in Molecular Biology and 7 papers in Pharmacology. Recurrent topics in Yoshimi Imura's work include Antiplatelet Therapy and Cardiovascular Diseases (7 papers), Inflammatory mediators and NSAID effects (7 papers) and Renin-Angiotensin System Studies (7 papers). Yoshimi Imura is often cited by papers focused on Antiplatelet Therapy and Cardiovascular Diseases (7 papers), Inflammatory mediators and NSAID effects (7 papers) and Renin-Angiotensin System Studies (7 papers). Yoshimi Imura collaborates with scholars based in Japan, United States and Belgium. Yoshimi Imura's co-authors include Kohei Nishikawa, Zen‐ichi Terashita, Yasuo Sugiyama, Ryuichi Tozawa, Tomoyuki Nishimoto, Yuichiro Amano, Yumiko Shibouta, Hiromitsu Fuse, Masayuki Tanaka and Hideki Igata and has published in prestigious journals such as Biochemical and Biophysical Research Communications, Kidney International and Journal of Medicinal Chemistry.

In The Last Decade

Yoshimi Imura

30 papers receiving 961 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Yoshimi Imura Japan 16 338 246 188 162 133 31 1.0k
Haruhisa Otani Japan 18 460 1.4× 110 0.4× 453 2.4× 155 1.0× 158 1.2× 46 1.5k
Sam Rebello United States 21 215 0.6× 357 1.5× 133 0.7× 143 0.9× 256 1.9× 58 1.1k
Johan Beetens Belgium 17 221 0.7× 163 0.7× 82 0.4× 57 0.4× 159 1.2× 39 829
Serge Simonet France 17 237 0.7× 236 1.0× 112 0.6× 80 0.5× 342 2.6× 39 842
I. Myara France 23 370 1.1× 121 0.5× 264 1.4× 216 1.3× 102 0.8× 60 1.5k
Toshimi Kanbe Japan 18 249 0.7× 174 0.7× 243 1.3× 52 0.3× 124 0.9× 38 1.0k
G A FitzGerald United States 10 180 0.5× 294 1.2× 115 0.6× 61 0.4× 136 1.0× 14 888
Μakoto Tanaka Japan 19 407 1.2× 116 0.5× 86 0.5× 58 0.4× 154 1.2× 67 1.0k
Timo P. Hiltunen Finland 19 507 1.5× 407 1.7× 276 1.5× 338 2.1× 189 1.4× 49 1.4k
Steven S. Mundt United States 15 375 1.1× 113 0.5× 398 2.1× 432 2.7× 173 1.3× 23 1.4k

Countries citing papers authored by Yoshimi Imura

Since Specialization
Citations

This map shows the geographic impact of Yoshimi Imura's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yoshimi Imura with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yoshimi Imura more than expected).

Fields of papers citing papers by Yoshimi Imura

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yoshimi Imura. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yoshimi Imura. The network helps show where Yoshimi Imura may publish in the future.

Co-authorship network of co-authors of Yoshimi Imura

This figure shows the co-authorship network connecting the top 25 collaborators of Yoshimi Imura. A scholar is included among the top collaborators of Yoshimi Imura based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yoshimi Imura. Yoshimi Imura is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hirota, Takashi, et al.. (2021). Application of a simple measuring method to evaluate the fecal microflora of dairy cows in the summer season. Journal of Advanced Veterinary and Animal Research. 8(2). 307–307. 1 indexed citations
2.
3.
Ojima, Mami, Hideki Igata, Masayuki Tanaka, et al.. (2010). In Vitro Antagonistic Properties of a New Angiotensin Type 1 Receptor Blocker, Azilsartan, in Receptor Binding and Function Studies. Journal of Pharmacology and Experimental Therapeutics. 336(3). 801–808. 122 indexed citations
4.
Takagi, Mitsuhiro, et al.. (2009). Effects of Gamma-Aminobutyric Acid Administration on Health and Growth Rate of Group-Housed Japanese Black Calves Fed Using an Automatic Controlled Milk Feeder. Journal of Veterinary Medical Science. 71(5). 651–656. 10 indexed citations
5.
Tozawa, Ryuichi, et al.. (2004). Comparison of the effects of pioglitazone and rosiglitazone on macrophage foam cell formation. Biochemical and Biophysical Research Communications. 323(3). 782–788. 43 indexed citations
6.
Amano, Yuichiro, et al.. (2003). Lipid-lowering effects of TAK-475, a squalene synthase inhibitor, in animal models of familial hypercholesterolemia. European Journal of Pharmacology. 466(1-2). 155–161. 36 indexed citations
7.
Nishimoto, Tomoyuki, Ryuichi Tozawa, Yuichiro Amano, et al.. (2003). Comparing myotoxic effects of squalene synthase inhibitor, T-91485, and 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors in human myocytes. Biochemical Pharmacology. 66(11). 2133–2139. 64 indexed citations
8.
Nishimoto, Tomoyuki, Yuichiro Amano, Ryuichi Tozawa, et al.. (2003). Lipid‐lowering properties of TAK‐475, a squalene synthase inhibitor, in vivo and in vitro. British Journal of Pharmacology. 139(5). 911–918. 59 indexed citations
9.
Matsuo, Takanori, et al.. (2002). Renal Protective Effect of Candesartan Cilexetil in Spontaneously Hypercholesterolemic Rats. The Japanese Journal of Pharmacology. 88(3). 300–306. 3 indexed citations
10.
Noda, Masakuni, Takanori Matsuo, M Ohta, et al.. (2001). Involvement of Angiotensin II in Progression of Renal Injury in Rats With Genetic Non-insulin-Dependent Diabetes Mellitus (Wistar Fatty Rats). The Japanese Journal of Pharmacology. 85(4). 416–422. 22 indexed citations
11.
Noda, Masakuni, Takanori Matsuo, Ryo Fukuda, et al.. (1999). Effect of candesartan cilexetil (TCV-116) in rats with chronic renal failure. Kidney International. 56(3). 898–909. 43 indexed citations
12.
13.
14.
Imura, Yoshimi, Yoshihiro Kiyota, Yasuo Nagai, Kohei Nishikawa, & Zen‐ichi Terashita. (1995). Beneficial effect of CV-4151 (isbogrel), a thromboxane A2 synthase inhibitor, in a rat middle cerebral artery thrombosis model. Thrombosis Research. 79(1). 95–107. 8 indexed citations
15.
Shibouta, Yumiko, Zen‐ichi Terashita, Yoshimi Imura, et al.. (1991). Involvement of thromboxane A2, leukotrienes and free radicals in puromycin nephrosis in rats. Kidney International. 39(5). 920–929. 20 indexed citations
16.
Imura, Yoshimi, Zen‐ichi Terashita, Yumiko Shibouta, Yoshiyuki Inada, & Kohei Nishikawa. (1990). Antagonistic action of AA-2414 on thromboxane A2/prostaglandin endoperoxide receptor in platelets and blood vessels.. The Japanese Journal of Pharmacology. 52(1). 35–43. 14 indexed citations
17.
Terashita, Zen‐ichi, et al.. (1989). Endothelin-induced sudden death and the possible involvement of platelet activating factor (PAF). Life Sciences. 45(20). 1911–1918. 24 indexed citations
18.
YOSHIOKA, YOSHIO, et al.. (1989). Platelet activating factor (PAF) antagonists: synthesis and structure-activity studies of novel PAF analogs modified in the phosphorylcholine moiety. Journal of Medicinal Chemistry. 32(1). 56–64. 11 indexed citations
19.
Imura, Yoshimi, et al.. (1988). The thromboxane A2/prostaglandin endoperoxide receptor antagonist activity of CV-4151, a thromboxane A2 synthetase inhibitor. European Journal of Pharmacology. 147(3). 359–365. 21 indexed citations
20.
Terashita, Zen‐ichi, et al.. (1985). Is platelet activating factor (PAF) a mediator of endotoxin shock?. European Journal of Pharmacology. 109(2). 257–261. 203 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Haruhisa Otani Breakdown of academic impact, for papers by Sam Rebello Breakdown of academic impact, for papers by Johan Beetens Breakdown of academic impact, for papers by Serge Simonet Breakdown of academic impact, for papers by I. Myara Breakdown of academic impact, for papers by Toshimi Kanbe Breakdown of academic impact, for papers by G A FitzGerald Breakdown of academic impact, for papers by Μakoto Tanaka Breakdown of academic impact, for papers by Timo P. Hiltunen Breakdown of academic impact, for papers by Steven S. Mundt
Rankless by CCL
2026